LWCFA
MDGL icon

Loring Wolcott & Coolidge Fiduciary Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$268K Hold
500
– – ﹤0.01% 295
2026
Q1 		$260K Hold
500
– – ﹤0.01% 292
2025
Q4 		$250K Hold
500
– – ﹤0.01% 293
2025
Q3 		$212K Buy
+500
New +$187K ﹤0.01% 309

Other funds holding MDGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's MDGL Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 500 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #295.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in MDGL in Q3 2025 and has held it in 4 quarters since. 227 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Loring Wolcott & Coolidge Fiduciary Advisors held 500 shares of Madrigal Pharmaceuticals worth $268K as of Q2 2026.
  • Loring Wolcott & Coolidge Fiduciary Advisors left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #295 holding.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 227 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.